Overview

A Long-term, Safety, Tolerability, and Efficacy Study of Retigabine Immediate-release (IR) in Asian Adults With Partial Onset Seizures

Status:
Completed

Trial end date:
2017-09-13

Target enrollment:

Participant gender:

Summary

This is a multicentre, long-term, open-label extension (OLE) study to assess the long-term safety, tolerability and efficacy of retigabine immediate-release (IR) as adjunctive therapy in adult Asian subjects with drug-resistant partial-onset seizures (POS).

Phase:

Phase 3

Details

Lead Sponsor:

GlaxoSmithKline

Treatments:

Ezogabine